Compounds, compositions and methods for treating sepsis
AssigneeFerring B.V.
InventorsAnne Louise Søberg KJØLBYE, Nis Agerlin WINDELØV, Derek C. ANGUS, James A. RUSSELL
Life of this patent
Estimating the term…
Abstract
There are disclosed herein compositions comprising selepressin for use in treating sepsis in a patient. The composition comprising selepressin may be administered within six hours from when the patient requires vasopressor therapy. The patients may have a serum lactate concentration of less than about 2 mmol/L prior to treatment and/or a ratio of partial pressure arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) of greater than about 200 prior to treatment. Related methods also are disclosed.
Claims25
A composition comprising selepressin for use in treating sepsis in a patient requiring vasopressor therapy, wherein the composition comprising selepressin is administered to the patient within six hours from when the patient requires the vasopressor therapy.
A composition comprising selepressin for use in treating sepsis in a patient, wherein the patient has a serum lactate concentration of less than 2 mmol/L prior to treatment.
A composition comprising selepressin for use in treating sepsis in a patient, wherein the patient has a ratio of partial pressure arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) of greater than about 260 prior to treatment.
A composition comprising selepressin for use according to any preceding claim, wherein the sepsis is vasopressor dependent sepsis.
A method of treating sepsis in a patient requiring vasopressor therapy, comprising administering a composition comprising selepressin to the patient within six hours from when the patient requires the vasopressor therapy.
A method of treating sepsis, comprising administering a composition comprising selepressin to a patient in need thereof, wherein the patient has a serum lactate concentration of less than 2 mmol/L prior to treatment.
A method of treating sepsis, comprising administering a composition comprising selepressin to a patient in need thereof, wherein the patient has a ratio of partial pressure arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) of greater than about 260 prior to treatment.
A composition comprising selepressin for use or method according to any preceding claim, wherein the selepressin is administered intravenously or subcutaneously.
A composition comprising selepressin for use or method according to any preceding claim, wherein the selepressin is administered by continuous intravenous infusion at a dose rate from about 1.7 ng/kg/min to about 7.5 ng/kg/min.
A composition comprising selepressin for use or method according to any preceding claim, wherein the selepressin is administered together with a further antihypotensive agent.
A composition comprising selepressin for use or method according to any preceding claim, wherein the selepressin is administered together with an inotropic agent.
Dependencies are inferred from the claim text.